A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the ...
News-Medical.Net on MSN
Whole-genome sequencing improves PARP inhibitor treatment prediction
A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...
Researchers at The Institute of Cancer Research, London identified the CIP2A–TOPBP1 complex as a master regulator of DNA repair during mitosis, coordinating backup pathways that protect chromosomes ...
The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...
Assays to measure homologous recombination deficiency (HRD) in ovarian cancer vary widely, underscoring the need for standardization, since inconsistent assay results can influence treatment decisions ...
A major advance in cell biology has revealed how our cells safeguard their genetic material during one of the most vulnerable moments in their life cycle. The study identifies a specific protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback